DOAJ Open Access 2026

The role of antibody-drug conjugates in the treatment of lung cancer

Tanya Zlatanova Aynura Changalova Urska Janzic Urska Janzic

Abstrak

Over the las0t decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges.

Topik & Kata Kunci

Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Penulis (4)

Tanya Zlatanova

Aynura Changalova

Urska Janzic

Format Sitasi

APA MLA BibTeX

Zlatanova, T., Changalova, A., Janzic, U., Janzic, U. (2026). The role of antibody-drug conjugates in the treatment of lung cancer. https://doi.org/10.3389/fonc.2026.1757564

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.3389/fonc.2026.1757564

Informasi Jurnal

Tahun Terbit: 2026
Sumber Database: DOAJ
DOI: 10.3389/fonc.2026.1757564
Akses: Open Access ✓